BioMimetix ’s Post

ENOR Papers! 📌📇 Have a look on this article published by Souček's group if you want to know more about oxysterols signalling in early-stage luminal breast cancer. https://lnkd.in/dRtPk4hY

Interesting overview of the use of theranostics for Neurooncology and future perspectives on research needs https://lnkd.in/eFvHTgyh

New tumor spatial mapping tool will help clinicians assess aggressiveness of cancer and personalize treatment . FuncOmap directly maps the functional states of oncoproteins in patients' tumour sections, so that clinicians can predict which treatments will work best. #ScienceDailynews #InnovativeResearch #NextGenScience #ExploringFrontiers

When I evaluate a diagnostic test as a health care provider the biggest question I ask is, "Will this change how I treat a patient?" #DCISionRT has proven now in over 2,000 patients to change clinician behavior. Importantly #radiation recommendations for #DCIS patients changed in both directions (more and less). The study showed, "On multivariable analysis, DS had the strongest influence on final RT recommendation (odds ratio 22.2, 95% confidence interval 16.3–30.7), which was eightfold greater than clinicopathologic features." When I evaluate this study as a #breastcancer #survivor, I am thrilled to see that DCIS patients now have a voice in their care conversations. Patient preference was the second most influential factor in the final radiation therapy recommendation. This is #shareddecisionmaking at its best!

Primary and distant metastatic sites in patients with renal cell carcinoma have distinct molecular features, according to the latest research by Shuchi Gulati et al.: https://lnkd.in/g_K9Tvp2 #Oncology

Personalised medicine in radiation therapy helping better inform treatment decisions for our patients.

Our latest study published in the Journal of Hematology and Oncology sheds light on abnormalities in the plasma von Willebrand Factor (vWF) system in aggressive hematological malignancies. 🩸 The study investigates changes in vWF-related parameters and the prevalence of ADAMTS13 autoantibodies in patients with newly diagnosed or relapsed acute leukemias or aggressive non-Hodgkin lymphomas. 🔍 Key Findings: Elevated levels of factor VIII, vWF:Ag, vWF activity, and vWF:CBA were observed, while ADAMTS13 protein levels were reduced in most patients. Patients with lymphomas showed significantly higher levels of these parameters compared to those with acute leukemias. Surprisingly, 63.3% of patients exhibited the presence of ADAMTS13 autoantibodies, despite the absence of thrombotic thrombocytopenic purpura (TTP). Notably, there was no correlation found between ADAMTS13 protein levels and vWF-related parameters or ADAMTS13 autoantibodies. 📝 These findings provide valuable insights into the pathophysiological processes underlying aggressive hematological malignancies and highlight the importance of further research in this area. 🔗 For more details, read the full article here: https://lnkd.in/gUfEHxYJ #Research #Hematology #Oncology #Science #MedicalResearch

The PREDICT study, a landmark trial enrolling 2,000+ women with #DCIS across 63 U.S. academic and community centers, is now published in the Annals of Surgical Oncology. This research reinforces the clinical utility of our #DCISionRT test in personalizing treatment, demonstrating a 38% change in radiation therapy (RT) recommendations. This prospective study highlights the test’s ability to help avoid both over- and undertreatment of DCIS. Learn how #DCISionRT empowers informed decisions and improves patient care. https://lnkd.in/gH7Fk78p

Proud of our #nucmed chief resident Divya Yadav, who did a beautiful job with this research project, taking it from data collection / analysis to Radiological Society of North America (RSNA) abstract to publication 👏 over the course of the past year. In this study, we show that dural based #metastases, a rare but important diagnosis in patients with #prostatecancer, can be differentiated from #meningioma, the most common brain tumor, using #PSMA #PET. This highlights targeted PET as an important adjunct modality in the management of patients with #prostatecancer https://lnkd.in/e9nyXf7n Many thanks to our multi-disciplinary team Silvina Dutruel, MD Andres Ricaurte-Fajardo Susan Pannullo Jonathan Knisely Rituraj Upadhyay Joshua Palmer Scott Tagawa Joseph Osborne Andrew Brandmaier Weill Cornell Medicine Cornell Molecular Imaging and Therapeutics

Big news in oncology! The study found that a CT radiomics model predicts treatment response and survival in colorectal liver metastases patients undergoing transarterial Yttrium-90 radioembolization (TARE). Key radiomic features Energy and Maximal Correlation Coefficient (MCC) reflect tumor heterogeneity, guiding personalized treatment strategies. Stay tuned for more! #CTRadiomics #PrecisionMedicine #LiverMetastases #TARE #OncologyResearch 🌟 Jonel Trebicka, UKM https://lnkd.in/ekbHgP3C